Cancer Drug Combos Causing Cost Effectiveness Headaches

Barcelona — The increasing use of drug combinations in oncology will lead to greater uncertainty over cost-effectiveness, argue leading experts, with patients potentially left unable to access combination therapies that offer improved outcomes but at inflated cost to the health service. Carla Deakin, programme director, Commercial & Managed Access […]

Leave a Reply